BioNTech SE (BNTX) EBITDA (2018 - 2025)

BioNTech SE (BNTX) has 8 years of EBITDA data on file, last reported at -$375.8 million in Q4 2025.

• In Q4 2025, EBITDA fell 336.63% year-over-year to -$375.8 million; the TTM figure through Dec 2025 stood at -$1.4 billion (down 50.58% YoY), while the FY2025 annual figure was -$1.6 billion, down 13.02% from the prior year.
• EBITDA declined to -$375.8 million in Q4 2025, from -$54.8 million in the prior quarter.
• Across five years, EBITDA topped out at $5.6 billion in Q3 2021 and bottomed at -$985.8 million in Q2 2024.
• A 5-year average of $1.5 billion and a median of $385.7 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2021 — EBITDA surged 5574.02% — and 2025, when it sank 336.63%.
• Year by year, EBITDA stood at $5.4 billion in 2021, then tumbled by 37.51% to $3.4 billion in 2022, then slumped by 83.15% to $566.2 million in 2023, then sank by 71.95% to $158.8 million in 2024, then slumped by 336.63% to -$375.8 million in 2025.
• The last three EBITDA figures came in at -$375.8 million (Q4 2025), -$54.8 million (Q3 2025), and -$481.1 million (Q2 2025), per Business Quant data.

Peer Comparison